Anixa Biosciences Receives Notice of Allowance from USPTO for Ovarian Cancer Vaccine
Rhea-AI Summary
Anixa Biosciences (NASDAQ: ANIX) has received a Notice of Allowance from the USPTO for a key patent application covering its ovarian cancer vaccine technology. The patent includes broad claims related to methods of eliciting an immune response targeting Anti-Mullerian Hormone Receptor, Type II (AMHR2), which is considered a promising target for ovarian cancer prevention and treatment.
The vaccine, being developed in collaboration with Cleveland Clinic and the National Cancer Institute, represents a novel approach particularly focused on high-risk populations, including individuals with BRCA mutations or family history of ovarian cancer. The allowed claims specifically cover methods of administering an immunogenic composition comprising a nucleic acid encoding the AMHR2 polypeptide's extracellular domain to elicit an AMHR2-specific immune response.
Positive
- Secured USPTO Notice of Allowance for key ovarian cancer vaccine patent
- Patent provides broad protection for vaccine technology components and delivery mechanisms
- Strengthened intellectual property position in ovarian cancer prevention and treatment
Negative
- None.
News Market Reaction – ANIX
On the day this news was published, ANIX gained 1.27%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Anixa's ovarian cancer vaccine, being developed in collaboration with Cleveland Clinic and the National Cancer Institute, represents a novel approach to preventing and treating ovarian cancer, particularly among high-risk populations such as those carrying BRCA mutations or with a family history of the disease.
The allowed claims include methods of administering an immunogenic composition comprising a nucleic acid encoding the AMHR2 polypeptide, specifically the extracellular domain of human AMHR2, to elicit an AMHR2-specific immune response.
Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences, commented, "Receiving this Notice of Allowance from the USPTO is a significant milestone in our mission to develop a preventative and therapeutic ovarian cancer vaccine. The allowed claims provide broad protection for the various components and delivery mechanisms of our vaccine technology. This strengthens our intellectual property position and supports the continued advancement of our program."
About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on Twitter, LinkedIn, Facebook and YouTube.
Forward-Looking Statements
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.
Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808
View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-receives-notice-of-allowance-from-uspto-for-ovarian-cancer-vaccine-302408680.html
SOURCE Anixa Biosciences, Inc.
FAQ
What patent protection did Anixa Biosciences (ANIX) receive for its ovarian cancer vaccine?
Who are the development partners for Anixa's (ANIX) ovarian cancer vaccine?
What is the target population for Anixa's (ANIX) ovarian cancer vaccine?
What is the specific mechanism of Anixa's (ANIX) ovarian cancer vaccine?
